GlassScriptPhysician profile
John Llewelyn
NPI 1942209424
$2,025.73
in general payments reported to CMS, 2019-2025
22 companies · $29.54 in 2025
The $29.54 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $203 · 2021: $228 · 2022: $443 · 2023: $733 · 2024: $200 · 2025: $29.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.10 | 2019-2024 | |
| Myriad Women'S Health, INC. | $334.44 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $313.20 | 2019-2025 | Novasure, Aptima, Thinprep 2000 Processor |
| Myovant Sciences INC. | $116.58 | 2022 | |
| Intuitive Surgical, INC. | $91.68 | 2019 | |
| Sumitomo Pharma America, INC. | $76.17 | 2023-2024 | Myfembree |
| Organon LLC | $68.36 | 2021-2024 | Nexplanon |
| Coopersurgical, INC. | $64.67 | 2020-2024 | Endosee |
| Astellas Pharma US INC | $51.93 | 2021-2023 | Veozah |
| Agile Therapeutics, INC. | $39.00 | 2022 | |
| Lupin INC. | $38.46 | 2019-2020 | |
| Coloplast Corp | $33.67 | 2023 | Saffron |
| Boston Scientific Corporation | $33.42 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $32.64 | 2024 | |
| Pfizer INC. | $30.99 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.03 | 2023 | Truclear |
| Shield Therapeutics INC | $16.80 | 2023 | Accrufer |
| Smith+Nephew, INC. | $16.51 | 2021 | |
| Channel Medsystems, INC. | $15.62 | 2022 | |
| Evofem Biosciences, INC. | $12.14 | 2021 | |
| Therapeuticsmd, INC. | $12.06 | 2021 | |
| Merck Sharp & Dohme LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Llewelyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.